Biomedical Engineering Reference
In-Depth Information
19. Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo KM, Huston
JS. (2010) SEEDbodies: fusion proteins based on strand-
exchange engineered domain (SEED) CH3 heterodimers in
an Fc analogue platform for asymmetric binders or immuno-
fusions and bispecific antibodies. Protein Eng. Des. Sel. 23,
195-202.
20. Mueller BM, Romerdahl CA, Gillies SD, Reisfeld RA. (1990)
Enhancement of antibody-dependent cytotoxicity with a chi-
meric anti-GD2 antibody. J. Immunol. 144, 1382-1386.
21. Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM,
Armstrong EA, Benavente S, Gondi V, Hsu KT, Harari PM.
(2008) Mechanisms of acquired resistance to cetuximab: role
of HER (ErbB) family members. Oncogene 27, 3944-3956.
22. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C,
Park JO, Lindeman N, Gale CM, Zhao X, Christensen J,
Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T,
Lee C, Johnson BE, Cantley LC, Janne PA. (2007) MET
amplification leads to gefitinib resistance in lung cancer by
activating ERBB3 signaling. Science 316, 1039-1043.
23. Choi YJ, Rho JK, Jeon BS, Choi SJ, Park SC, Lee SS, KimHR,
Kim CH, Lee JC. (2010) Combined inhibition of IGFR
enhances the effects of gefitinib in H1650: a lung cancer
cell line with EGFR mutation and primary resistance to
EGFR-TK inhibitors. Cancer Chemother. Pharmacol. 66,
381-388.
24. Adjei AA. (2006) Novel combinations based on epidermal
growth factor receptor inhibition. Clin. Cancer Res. 12, 4446s-
4450s.
25. Kou G, Shi J, Chen L, Zhang D, Hou S, Zhao L, Fang C,
Zheng L, Zhang X, Liang P, Zhang X, Li B, Guo Y. (2010) A
bispecific antibody effectively inhibits tumor growth and
metastasis by simultaneous blocking vascular endothelial
growth factor A and osteopontin. Cancer Lett. 299, 130-
136.
26. Mabry R, Gilbertson DG, Frank A, Vu T, Ardourel D,
Ostrander C, Stevens B, Julien S, Franke S, Meengs B, Brody
J, Presnell S, Hamacher NB, Lantry M, Wolf A, Bukowski T,
Rosler R, Yen C, Anderson-Haley M, Brasel K, Pan Q,
Franklin H, Thompson P, Dodds M, Underwood S, Peterson
S, Sivakumar PV, Snavely M. (2010) A dual-targeting
PDGFRbeta/VEGF-A molecule assembled from stable anti-
body fragments demonstrates anti-angiogenic activity in vitro
and in vivo. MAbs. 2, 20-34.
27. Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva
M, Shaller CC, von MM, Shchaveleva I, Simmons HH, Marks
JD, Adams GP. (2008) Targeting ErbB2 and ErbB3 with a
bispecific single-chain Fv enhances targeting selectivity and
induces a therapeutic effect in vitro. Br. J. Cancer 99, 1415-
1425.
28. Huston JS, McCartney J, Tai MS, Mottola-Hartshorn C, Jin D,
Warren F, Keck P, Oppermann H. (1993) Medical applications
of single-chain antibodies. Int. Rev. Immunol. 10, 195-217.
29. Lindhofer H, Mocikat R, Steipe B, Thierfelder S. (1995)
Preferential species-restricted heavy/light chain pairing in
rat/mouse quadromas. Implications for a single-step purifica-
tion of bispecific antibodies. J. Immunol. 155, 219-225.
30. Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW,
Presta LG, Carter P. (1998) An efficient route to human
bispecific IgG. Nat. Biotechnol. 16, 677-681.
31. Ward ES, Gussow D, Griffiths AD, Jones PT, Winter G. (1989)
Binding activities of a repertoire of single immunoglobulin
variable domains secreted from Escherichia coli. Nature 341,
544-546.
32. Harmsen MM, De Haard HJ. (2007) Properties, production,
and applications of camelid single-domain antibody frag-
ments. Appl. Microbiol. Biotechnol. 77, 13-22.
33. Dimasi N, Gao C, Fleming R, Woods RM, Yao XT, Shirinian L,
Kiener PA, Wu H. (2009) The design and characterization of
oligospecific antibodies for simultaneous targeting of multiple
disease mediators. J. Mol. Biol. 393, 672-692.
34. Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A,
Bose S, McCarthy D, Zhu RR, Santora L, Davis-Taber R,
Kunes Y, Fung E, Schwartz A, Sakorafas P, Gu J, Tarcsa E,
Murtaza A, Ghayur T. (2007) Simultaneous targeting of mul-
tiple disease mediators by a dual-variable-domain immuno-
globulin. Nat. Biotechnol. 25, 1290-1297.
35. Jackman J, Chen Y, Huang A, Moffat B, Scheer JM, Leong SR,
Lee WP, Zhang J, Sharma N, Lu Y, Iyer S, Shields RL, Chiang
N, Bauer MC, Wadley D, Roose-Girma M, Vandlen R, Yansura
DG, Wu Y, Wu LC. (2010) Development of a two-part strategy
to identify a therapeutic human bispecific antibody that inhibits
IgE receptor signaling. J. Biol. Chem. 285, 20850-20859.
36. Gunasekaran K, Pentony M, Shen M, Garrett L, Forte C,
Woodward A, Ng SB, Born T, Retter M, Manchulenko K,
Sweet H, Foltz IN, Wittekind M, Yan W. (2010) Enhancing
antibody Fc heterodimer formation through electrostatic steer-
ing effects: applications to bispecific molecules and mono-
valent IgG. J. Biol. Chem. 285, 19637-19646.
37. Muda M, Gross AW, Dawson JP, He C, Kurosawa E,
Schweickhardt R, Dugas M, Soloviev M, Bernhardt A, Fischer
D, Wesolowski JS, Kelton C, Neuteboom B, Hock B. (2011)
Therapeutic assessment of SEED: a new engineered antibody
platform designed to generate mono- and bispecific antibodies.
Protein Eng. Des. Sel. 24, 447-454.
38. Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H,
Carano RA, Kasman I, Mai E, Young J, Zha J, Zhang Z, Ross S,
Schwall R, Colbern G, Merchant M. (2008) MetMAb, the one-
armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic
tumor growth and improves survival. Cancer Res. 68, 4360-
4368.
39. Pacchiana G, Chiriaco C, Stella MC, Petronzelli F, De SR,
Galluzzo M, Carminati P, Comoglio PM, Michieli P, Vigna E.
(2010) Monovalency unleashes the full therapeutic potential of
the DN-30 anti-Met antibody. J. Biol. Chem. 285, 36149-
36157.
40. Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant
M, Schwall R, Westphal M, Lamszus K. (2006) A novel one-
armed anti-c-Met antibody inhibits glioblastoma growth in
vivo. Clin. Cancer Res. 12, 6144-6152.
41. Neri D, Momo M, Prospero T, Winter G. (1995) High-affinity
antigen binding by chelating recombinant antibodies (CRAbs).
J. Mol. Biol. 246, 367-373.
Search WWH ::
Custom Search